Italian court upholds Aspen excessive pricing decision

An Italian court has upheld the Italian Antitrust Authority's decision to fine pharmaceutical company Aspen €5 million for abuse of dominance, backing the enforcer's benchmark for assessing whether the company had unfairly inflated the prices of cancer drugs.

Unlock unlimited access to all Global Competition Review content